Evidence map›Paper›PMID 36094896›Full record

ArticleJournal of medicinal chemistry2022

Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5.

Matteo Rossi Sebastiano, Diego Garcia Jimenez, Maura Vallaro, Giulia Caron, Giuseppe Ermondi

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. MK4 Repositioning for IAHSP: OvercomingACS chemical neuroscience · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matteo Rossi SebastianoMolecular Biotechnology and Health Sciences Department, CASSMedChem, University of Torino, via Quarello 15, 10135Torino, Italy.ORCID 0000-0002-9925-1904
Diego Garcia JimenezMolecular Biotechnology and Health Sciences Department, CASSMedChem, University of Torino, via Quarello 15, 10135Torino, Italy.ORCID 0000-0002-7247-1480
Maura VallaroMolecular Biotechnology and Health Sciences Department, CASSMedChem, University of Torino, via Quarello 15, 10135Torino, Italy.
Giulia CaronMolecular Biotechnology and Health Sciences Department, CASSMedChem, University of Torino, via Quarello 15, 10135Torino, Italy.ORCID 0000-0002-2417-5900
Giuseppe ErmondiMolecular Biotechnology and Health Sciences Department, CASSMedChem, University of Torino, via Quarello 15, 10135Torino, Italy.ORCID 0000-0003-3710-3102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a need of computational tools to rank bRo5 drug candidates in the very early phases of drug discovery when chemical matter is unavailable. In this study, we selected three compounds: (a) a Ro5 drug (Pomalidomide), (b) a bRo5 orally available drug (Saquinavir), and (c) a polar PROTAC (CMP 98) to focus on computational access to physicochemical properties. To provide a benchmark, the three compounds were first experimentally characterized for their lipophilicity, polarity, IMHBs, and chameleonicity. To reproduce the experimental information content, we generated conformer ensembles with conformational sampling and molecular dynamics in both water and nonpolar solvents. Then we calculated Rgyr, 3D PSA, and IMHB number. An innovative pool of strategies for data analysis was then provided. Overall, we report a contribution to close the gap between experimental and computational methods for characterizing bRo5 physicochemical properties.

Indexed as

Computational ChemistryDrug DiscoverySaquinavirMolecular Dynamics SimulationSolventsThalidomideWaterpomalidomideSaquinavirSolventsThalidomideWater

Identifiers

PMID36094896
PMCPMC9511483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.